New cocktail of cancer drugs tested in advanced tumors

NCT ID NCT03217747

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see if these combinations can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
avelumab (immunotherapy drug) combined with utomilumab, ivuxolimab, or radiation therapy
What this could lead to
If successful, this could point toward new combination treatments that help control advanced cancers by boosting the immune system.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants. The combinations may cause serious side effects or may not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.